SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014628880> ?p ?o ?g. }

Showing items 1 to 100 of ±125 with 100 items per page.

W2014628880 endingPage "460" @default.
W2014628880 startingPage "458" @default.
W2014628880 abstract "277 untreated multiple myeloma patients of stage 1 (n = 33), II (n = 106) and III (n = 138) entered the study. Patients of stage II presenting a progressive tumor (n = 64) initially or during observation (n = 14) were treated with MivP (remissions: 61%). 138 patients of stage III were randomized to receive MivP or VBAMDex treatment. 51% of MivP treated patients responded versus 70% of the VBAMDex group. 71 responders of stage II and III with stable disease were randomized on Ifn-alpha maintenance versus no maintenance treatment. The relapse rate in both groups was 50% after 7 months. 75% survival was greater than 36 months in stage II and 11 months in stage III patients." @default.
W2014628880 created "2016-06-24" @default.
W2014628880 creator A5000111467 @default.
W2014628880 creator A5000114096 @default.
W2014628880 creator A5004220462 @default.
W2014628880 creator A5008433641 @default.
W2014628880 creator A5009477787 @default.
W2014628880 creator A5018452381 @default.
W2014628880 creator A5019256481 @default.
W2014628880 creator A5024507792 @default.
W2014628880 creator A5024823042 @default.
W2014628880 creator A5029801921 @default.
W2014628880 creator A5032969951 @default.
W2014628880 creator A5034364254 @default.
W2014628880 creator A5034791268 @default.
W2014628880 creator A5037341064 @default.
W2014628880 creator A5038997634 @default.
W2014628880 creator A5046272940 @default.
W2014628880 creator A5051948177 @default.
W2014628880 creator A5052980195 @default.
W2014628880 creator A5053821652 @default.
W2014628880 creator A5053849812 @default.
W2014628880 creator A5060952450 @default.
W2014628880 creator A5061020169 @default.
W2014628880 creator A5068262794 @default.
W2014628880 creator A5079290836 @default.
W2014628880 creator A5082261075 @default.
W2014628880 creator A5082638530 @default.
W2014628880 creator A5084139618 @default.
W2014628880 creator A5086925246 @default.
W2014628880 creator A5088752635 @default.
W2014628880 date "1990-01-01" @default.
W2014628880 modified "2023-09-27" @default.
W2014628880 title "Melphalan and Prednisone (MP) versus Vincristine, BCNU, Adriamycin, Melphalan and Dexamethasone (VBAM Dex) Induction Chemotherapy and Interferon Maintenance Treatment in Multiple Myeloma" @default.
W2014628880 doi "https://doi.org/10.1159/000216820" @default.
W2014628880 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2092283" @default.
W2014628880 hasPublicationYear "1990" @default.
W2014628880 type Work @default.
W2014628880 sameAs 2014628880 @default.
W2014628880 citedByCount "21" @default.
W2014628880 countsByYear W20146288802012 @default.
W2014628880 crossrefType "journal-article" @default.
W2014628880 hasAuthorship W2014628880A5000111467 @default.
W2014628880 hasAuthorship W2014628880A5000114096 @default.
W2014628880 hasAuthorship W2014628880A5004220462 @default.
W2014628880 hasAuthorship W2014628880A5008433641 @default.
W2014628880 hasAuthorship W2014628880A5009477787 @default.
W2014628880 hasAuthorship W2014628880A5018452381 @default.
W2014628880 hasAuthorship W2014628880A5019256481 @default.
W2014628880 hasAuthorship W2014628880A5024507792 @default.
W2014628880 hasAuthorship W2014628880A5024823042 @default.
W2014628880 hasAuthorship W2014628880A5029801921 @default.
W2014628880 hasAuthorship W2014628880A5032969951 @default.
W2014628880 hasAuthorship W2014628880A5034364254 @default.
W2014628880 hasAuthorship W2014628880A5034791268 @default.
W2014628880 hasAuthorship W2014628880A5037341064 @default.
W2014628880 hasAuthorship W2014628880A5038997634 @default.
W2014628880 hasAuthorship W2014628880A5046272940 @default.
W2014628880 hasAuthorship W2014628880A5051948177 @default.
W2014628880 hasAuthorship W2014628880A5052980195 @default.
W2014628880 hasAuthorship W2014628880A5053821652 @default.
W2014628880 hasAuthorship W2014628880A5053849812 @default.
W2014628880 hasAuthorship W2014628880A5060952450 @default.
W2014628880 hasAuthorship W2014628880A5061020169 @default.
W2014628880 hasAuthorship W2014628880A5068262794 @default.
W2014628880 hasAuthorship W2014628880A5079290836 @default.
W2014628880 hasAuthorship W2014628880A5082261075 @default.
W2014628880 hasAuthorship W2014628880A5082638530 @default.
W2014628880 hasAuthorship W2014628880A5084139618 @default.
W2014628880 hasAuthorship W2014628880A5086925246 @default.
W2014628880 hasAuthorship W2014628880A5088752635 @default.
W2014628880 hasConcept C126322002 @default.
W2014628880 hasConcept C141071460 @default.
W2014628880 hasConcept C146357865 @default.
W2014628880 hasConcept C151730666 @default.
W2014628880 hasConcept C2776364478 @default.
W2014628880 hasConcept C2776611710 @default.
W2014628880 hasConcept C2776694085 @default.
W2014628880 hasConcept C2776755627 @default.
W2014628880 hasConcept C2778283404 @default.
W2014628880 hasConcept C2778684742 @default.
W2014628880 hasConcept C2778720950 @default.
W2014628880 hasConcept C2779429289 @default.
W2014628880 hasConcept C2780401358 @default.
W2014628880 hasConcept C71924100 @default.
W2014628880 hasConcept C86803240 @default.
W2014628880 hasConcept C90924648 @default.
W2014628880 hasConceptScore W2014628880C126322002 @default.
W2014628880 hasConceptScore W2014628880C141071460 @default.
W2014628880 hasConceptScore W2014628880C146357865 @default.
W2014628880 hasConceptScore W2014628880C151730666 @default.
W2014628880 hasConceptScore W2014628880C2776364478 @default.
W2014628880 hasConceptScore W2014628880C2776611710 @default.
W2014628880 hasConceptScore W2014628880C2776694085 @default.
W2014628880 hasConceptScore W2014628880C2776755627 @default.
W2014628880 hasConceptScore W2014628880C2778283404 @default.
W2014628880 hasConceptScore W2014628880C2778684742 @default.
W2014628880 hasConceptScore W2014628880C2778720950 @default.